GlassScriptPhysician profile
Emily Ankrom
NPI 1962803890
$191,772.57
in general payments reported to CMS, 2019-2025
35 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,443 · 2022: $36K · 2023: $18K · 2024: $42K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $20K · Food and Beverage: $12K · Consulting Fee: $3,950 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,667.36 |
| Travel and Lodging | $19,595.21 |
| Food and Beverage | $12,066.58 |
| Consulting Fee | $3,950.00 |
| Education | $160.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93,810.44 | 2021-2025 | |
| Lilly USA, LLC | $30,791.01 | 2022-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $29,585.86 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $25,865.98 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $3,161.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,009.36 | 2022 | |
| Janssen Scientific Affairs, LLC | $1,312.50 | 2023 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,287.11 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $1,135.89 | 2021-2024 | Zeposia |
| Genzyme Corporation | $508.84 | 2022-2025 | |
| Qol Medical, LLC | $312.37 | 2021-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $206.66 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Daiichi Sankyo INC. | $190.05 | 2021-2022 | |
| Braintree Laboratories, INC. | $169.87 | 2021-2025 | Suflave, Sutab |
| Ardelyx, INC. | $161.65 | 2022-2025 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $158.18 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $148.51 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Organon LLC | $115.73 | 2021-2023 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $111.08 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $103.70 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $93.27 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $85.98 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $60.99 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $56.17 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $52.69 | 2021-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $49.46 | 2024 | |
| Amgen INC. | $46.82 | 2021-2022 | |
| Evoke Pharma, INC. | $42.43 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.99 | 2023-2024 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $22.12 | 2021 | |
| Fresenius Kabi USA, LLC | $20.62 | 2023 | Idacio |
| Novo Nordisk INC | $17.86 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $16.62 | 2023 | Ultomiris |
| Mylan Institutional INC. | $15.33 | 2023 | Hulio |
| Ultragenyx Pharmaceutical INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Ankrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.